Non-glycemic effects of pioglitazone and incretin-based therapies

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.17, Iss.7, 2013-10, pp. : 739-742

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation

Current Pharmaceutical Design, Vol. 20, Iss. 31, 2014-09 ,pp. : 4953-4960

Bentham Science Publishers

Access to resources Recommend Favorite

Incretin Based Therapies: Bone Protective Effects

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 13, Iss. 4, 2013-12 ,pp. : 289-294

Bentham Science Publishers

Access to resources Recommend Favorite

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction

By Russell Sheldon

International Journal of Clinical Pharmacy, Vol. 35, Iss. 2, 2013-04 ,pp. : 159-172

Springer Publishing Company

Access to resources Recommend Favorite

The incretin effect and its potentiation by glucagon-like peptide 1-based therapies: a revolution in diabetes management

By Roges Octaviano A Baron Marilyn Philis-Tsimikas Athena

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 705-727

Informa Healthcare

Access to resources Recommend Favorite

Benefits with incretin-targeted therapies in T2DM

Inpharma, Vol. 1, Iss. 1596, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite